ArticlemedRxiv : the preprint server for health sciences2025
Hospital costs associated with mechanical left ventricular mechanical unloading devices during VA ECMO for adult cardiogenic shock.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
8 authors.
Funding
Abstract
Importance: No works to-date have described the financial burden and behaviors of left ventricular mechanical unloading (LVMU) for patients on veno-arterial extracorporeal membrane oxygenation (VA ECMO). Given the uptrending use of VA ECMO, describing its associated cost is essential for its continued uptake. Objective: We describe the inpatient costs of patients who were managed with ECMO for cardiogenic shock (CS) with and without LVMU. Design Setting and Participants: We conducted a retrospective cohort study of adult (age ≥18 years) patients who received ECMO at some point during their hospital stay and were non-post operative patients (e.g. medical CS) using the IBM MarketScan database. Data were extracted from 1/1/2008-12/31/2021. Exposures: The exposure of interest was the additional use of LVMU (intra aortic balloon pump, peripherally inserted left ventricular assist device [pVAD], or "other") added to ECMO. Costs were calculated daily, and modeled according to the daily status of ECMO, LVMU, ECMO+LVMU, or no device. Main Outcomes and Measures: Patient characteristic, including age, sex, comorbidities quantified using the Charlson Comorbidity Index (CCI), etiology of heart failure (acute myocardial infarction [AMI] vs chronic heart failure [CHF]), hospital and intensive care unit (ICU) length of stay (LOS) and total inpatient costs were described using descriptive statics between groups. The outcomes of interest were total inpatient costs. Secondary outcomes included in-hospital mortality, and hospital and intensive care unit (ICU) length of stays (LOS). We stratified patients by receipt of LVMU, and used propensity score matching from patient level characteristics to balance the use of LVMU between groups. Cost outcomes were modeled using mixed effects linear regression clustered on matched groups and reporting incident rate ratios (IRR). LOS and mortality outcomes were modeled using Poisson (IRR) and logistic (adjusted odds ratio [aOR]) regression, respectively, conditional on matched groups. Results: Enrolled patients (n=1,596) were 56 years old (interquartile range [IQR] 47 to 62), had an ICU LOS of 9 (3 to 19) days, and a hospital length of stay of 18 (7 to 35) days, which were not different between groups. Patients who received LVMU had a higher CCI ( Conclusions and Relevance: CS patients managed with VA ECMO + LVMU had significantly increased cost, significantly longer LOS, and significantly decreased mortality compared to ECMO alone. Understanding the impact of LVMU on the cost of an ECMO course will aid appropriate resource allocation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.